Novartis' new heart failure medicine LCZ696 approved by FDA
Novartis announced the FDA has approved Entresto(TM) (sacubitril/valsartan) tablets, previously known as LCZ696, for treatment of heart failure with reduced ejection fraction. Entresto will be available on prescription for patients whose condition is classified NYHA class II-IV. July 07, 2015